Breaking the Limits of Neurosurgical Vision
Brain Navi Biotechnology’s KrystoLens Wins National Innovation Award
Brain Navi Biotechnology has once again achieved notable success at the 22nd National Innovation Awards, where its innovative medical device—the KrystoLens—was honored with the “Innovative Medical Devices and Diagnostic Technology Award” under the Corporate Startup category. This recognition highlights the R&D strength and clinical potential of Taiwan’s biomedical startups in the field of advanced neurosurgical medical devices, earning high praise from the judging panel.
Currently, most neuroendoscopic systems used in clinical practice are reusable and require multiple post-operative cleaning, disinfection, and sterilization steps. These processes are not only complex and time-consuming but also demand significant human resources and increase hospitals’ reprocessing management burden. Even after sterilization, a potential risk of cross-contamination remains. Additionally, preoperative assembly and calibration procedures are relatively complex, which may prolong operating room preparation time and impact overall workflow efficiency.
Dr. Chieh-Hsiao Chen, CEO of Brain Navi Biotechnology, emphasized that insights from frontline clinical practice have driven the company’s focus on minimizing surgical trauma, shortening recovery time, and improving surgical efficiency while ensuring surgeon operability and patient safety. To meet these needs, Brain Navi Biotechnology has developed a single-use, EO-sterilized neuroendoscope with a plug-and-play design that reduces cross-infection risk, eliminates reprocessing, shortens preoperative setup time, and enhances operating room efficiency. Featuring the KrystoLens fully transparent sheath, the system overcomes the limited field of view of traditional endoscopes, enabling surgeons to visualize both lesions and surrounding tissues simultaneously, reduce blind spots, and enhance precision and safety during tumor and hemorrhage procedures.
The disposable medical devices not only help reduce labor and time costs but also improve the consistency of healthcare quality, allowing medical teams to focus more resources on clinical decision-making and patient care. According to research compiled by ScienceDirect, a database of peer-reviewed journals and book chapters under the international academic publisher Elsevier, approximately 22.6 million people worldwide suffer from conditions requiring neurosurgical intervention each year, with around 13.8 million patients undergoing surgery. In Taiwan alone, the annual number of brain-related surgeries reaches approximately 100,000 to 160,000 cases.
Looking ahead, in response to global population aging and the rising prevalence of neurological diseases, Brain Navi Biotechnology will continue to advance innovation in neurosurgical medical devices. By supporting healthcare systems in meeting the demands of high-volume neurosurgical procedures, the company aims to enhance clinical efficiency and patient safety—fulfilling its long-term vision of benefiting humanity and saving more lives.
